Overview

International Study to Predict Optimised Treatment - in Depression

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.
Phase:
Phase 4
Details
Lead Sponsor:
BRC Operations Pty. Ltd.
Treatments:
Citalopram
Dexetimide
Sertraline
Venlafaxine Hydrochloride